While there seems to be a debate related to the dystrophin being produced by eteplirsen and whether or not it has proven to be correlated with a clinical benefit, I believe the FDA guidance on accelerated approval requires dystrophin production only be "reasonably likely to predict" clinical benefit.
http://www.thestreet.com/story/11906821/1/a-dmd-expert-and-mother-calls-for-eteplirsens-rapid-approval.html?cm_ven=RSSFeed
http://www.thestreet.com/story/11906821/1/a-dmd-expert-and-mother-calls-for-eteplirsens-rapid-approval.html?cm_ven=RSSFeed
No comments:
Post a Comment